Karyopharm Therapeutics (KPTI) Research & Development (2016 - 2025)
Historic Research & Development for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $27.7 million.
- Karyopharm Therapeutics' Research & Development fell 1692.09% to $27.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $125.6 million, marking a year-over-year decrease of 1229.82%. This contributed to the annual value of $125.6 million for FY2025, which is 1229.82% down from last year.
- Per Karyopharm Therapeutics' latest filing, its Research & Development stood at $27.7 million for Q4 2025, which was down 1692.09% from $30.5 million recorded in Q3 2025.
- Karyopharm Therapeutics' 5-year Research & Development high stood at $45.8 million for Q3 2021, and its period low was $27.7 million during Q4 2025.
- For the 5-year period, Karyopharm Therapeutics' Research & Development averaged around $35.9 million, with its median value being $35.0 million (2024).
- Data for Karyopharm Therapeutics' Research & Development shows a peak YoY increase of 3039.35% (in 2022) and a maximum YoY decrease of 3154.25% (in 2022) over the last 5 years.
- Quarter analysis of 5 years shows Karyopharm Therapeutics' Research & Development stood at $44.0 million in 2021, then decreased by 29.7% to $30.9 million in 2022, then increased by 27.31% to $39.4 million in 2023, then fell by 15.44% to $33.3 million in 2024, then dropped by 16.92% to $27.7 million in 2025.
- Its Research & Development stands at $27.7 million for Q4 2025, versus $30.5 million for Q3 2025 and $32.8 million for Q2 2025.